18
Participants
Start Date
June 30, 2009
Primary Completion Date
February 29, 2012
Study Completion Date
February 29, 2012
Imprime PGG
Imprime PGG, 4 mg/kg, i.v. over 2 hr, weekly in 6 week cycles and Cetuximab, initial dose will be 400 mg/m2 via i.v., and subsequent doses will be 250 mg/m2 via i.v., weekly in 6 week cycles
University of Minnesota, Minneapolis
Memorial Sloane-Kettering Cancer Research Center, New York
Mary Crowley Medical Research Center, Dallas
Lead Sponsor
HiberCell, Inc.
INDUSTRY